{
    "2021-01-28": [
        [
            {
                "time": "2020-12-31",
                "original_text": "贝达药业：2020年度净利预增155%-185%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "净利",
                        "预增",
                        "155%",
                        "185%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-12-31",
                "original_text": "贝达药业(300558.SZ)预计2020年度归母净利润同比增长155.00%至185.00%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "归母净利润",
                        "同比增长",
                        "155.00%",
                        "185.00%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-12-31",
                "original_text": "贝达药业：2020年净利润同比预增155%至185%",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "净利润",
                        "同比预增",
                        "155%",
                        "185%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "专访贝达药业丁列明：拓荒中国创新抗癌药，打造“非凡TKI”",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "丁列明",
                        "创新抗癌药",
                        "非凡TKI"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-11-01",
                "original_text": "港股IPO|贝达药业拟赴港上市，旗下肺癌国产新药已获批上市",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "港股IPO",
                        "肺癌国产新药",
                        "获批上市"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-12-31",
                "original_text": "2020年四季度基金医药持仓点评：四季度公募基金医药重仓持股小幅下降 头部聚集趋势延续",
                "features": {
                    "keywords": [
                        "基金",
                        "医药持仓",
                        "公募基金",
                        "重仓持股",
                        "头部聚集"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}